A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
A041702 is closed to accrual, effective July 15, 2022
A041702, Step 1 registration, is closed to accrual, effective November 1, 2022
